NEMAURA MEDICAL INC - NMRD STOCK NEWS

Nemaura Medical (NASDAQ: NMRD) announced participation at the Benzinga Global Small Cap Conference on May 14, 2021. CEO Faz Chowdhury will present at 3:15 PM ET. One-on-one meetings with Dr. Chowdhury can be arranged post-conference.

The company develops non-invasive wearable diagnostic devices, specifically sugarBEAT® and proBEAT™. With a focus on diabetes management, sugarBEAT® is a CE marked Class IIb medical device currently under FDA review. Nemaura operates in a market projected to exceed $59 billion by 2025 for Type 2 diabetes.

Nemaura Medical, Inc. (NASDAQ: NMRD) has provided a letter to shareholders summarizing an update call on April 28, 2021. The call addressed the ongoing growth of the BEATdiabetes program and preparations for product launches in Europe and the U.S. Following the successful launch, the company initiated a pilot program involving 200 U.S. users and plans to hire additional staff in the UK. Nemaura expects to recognize revenue in Q2 2021, a significant milestone. The company holds approximately $31.8 million in cash as of March 31, 2021, and has avoided dilutive funding.

Nemaura Medical (NASDAQ: NMRD) will conduct a shareholder update call on April 28, 2021, at 4:30 PM ET. Participants need to pre-register to attend. The call will address pre-submitted questions, with dial-in options available for those without internet access. Nemaura develops non-invasive wearable diagnostic devices, including sugarBEAT®, a glucose monitor, and proBEAT™, launched as a general wellness product. The company is positioned in the rapidly growing diabetes and health-tech markets.

Nemaura Medical, Inc. (NASDAQ: NMRD) appointed Samantha Sanders as Global Head of Digital Programs on April 15, 2021. With over 20 years in project management and customer service in the medical device and pharmaceutical sectors, Sanders will enhance Nemaura's digital product design, placement, and customer service. She previously contributed to CE and FDA-certified medical products' commercialization. Nemaura aims to leverage her expertise to optimize user access to its health programs like BEAT®diabetes and the innovative sugarBEAT® system, potentially impacting its market presence positively.

Nemaura Medical (NASDAQ: NMRD) has launched its BEAT^®diabetes app on Google Play and iOS. This app offers personalized suggestions for diet and lifestyle changes to help manage and potentially reverse Type 2 diabetes. It features an AI avatar, Lena, who learns from user input to provide ongoing support. Additionally, pilot programs for the proBEAT^™ glucose monitoring patch, which syncs with the app, are commencing. This innovation aims to enhance lifestyle management and is positioned within the growing diabetes and wellness markets.

Nemaura Medical, Inc. (NASDAQ: NMRD) announced the retention of Paul Kennedy as an advisor for its commercial growth initiatives. Kennedy has significant bio and medtech experience, notably as a former CEO of Novo Nordisk in France. His extensive industry network is expected to bolster Nemaura's market efforts. The company is focused on developing non-invasive wearable diagnostic devices like sugarBEAT®, a continuous glucose monitor, and proBEAT™, utilizing AI for digital healthcare. Nemaura aims to tap into the growing global diabetes market, projected to reach nearly $59 billion by 2025.

Nemaura Medical, Inc. (NASDAQ: NMRD) announced its submission to the G-BA for approval of the sugarBEAT® glucose monitoring device. The G-BA is a critical decision-making body in Germany that oversees healthcare services. The company aims to enhance its market penetration in Germany, which has 73 million insured individuals. If reimbursed, Nemaura could access a total addressable market exceeding $150 billion for diabetes management. Nemaura is also developing the proBEAT™ device, further expanding its product portfolio.

Nemaura Medical (NASDAQ: NMRD), a medical technology firm, announces CEO Faz Chowdhury will present at Maxim Group's Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. Investors can register to view his presentation and request 1x1 meetings afterward. Nemaura focuses on non-invasive wearable diagnostic devices, including sugarBEAT® and proBEAT™, aimed at managing diabetes. The company targets the growing diabetes and wearable health-tech markets, estimated to be worth nearly $59 billion and over $60 billion, respectively, by 2025 and 2023.

Nemaura Medical (Nasdaq: NMRD) announced the appointment of Alistair Longmuir as an advisor for its global product manufacture strategy. His experience in the medical device field is expected to enhance Nemaura's commercial manufacturing partnerships. Longmuir, with over 30 years in engineering, previously held leadership roles at Johnson & Johnson and Lifescan, where he led the development of blood glucose monitoring devices. He aims to aid Nemaura in improving its offerings and expanding into new areas, particularly in diabetes care.